Celcuity Amends Loan Agreement and Launches Offerings

Celcuity ( (CELC) ) just unveiled an update.

On July 28, 2025, Celcuity Inc. announced amendments to its loan agreement with Innovatus Life Sciences Lending Fund and Oxford Finance, allowing for the issuance of convertible senior notes and common stock. The company launched public offerings to raise $150 million through convertible notes due 2031 and $75 million through common stock, intending to use the proceeds for various corporate purposes. Celcuity also reported preliminary financial results, with cash and investments at $168.4 million as of June 30, 2025, down from $283.1 million the previous year. The company plans to draw an additional $30 million under its Term D Loan following positive clinical trial results.

The most recent analyst rating on (CELC) stock is a Buy with a $29.00 price target. To see the full list of analyst forecasts on Celcuity stock, see the CELC Stock Forecast page.

Spark’s Take on CELC Stock

According to Spark, TipRanks’ AI Analyst, CELC is a Neutral.

Celcuity’s stock score of 43.73 reflects the challenges faced by early-stage biotech firms. The company’s financial performance is weak due to lack of revenue and high expenses. Technical analysis shows a neutral to slightly negative outlook, while valuation metrics are poor due to negative earnings. Despite these challenges, the earnings call provided a positive outlook with potential future revenue and strong financial positioning. The overall score indicates significant risks but potential for future growth if clinical and financial milestones are achieved.

To see Spark’s full report on CELC stock, click here.

More about Celcuity

Celcuity is a clinical-stage biotechnology company focused on developing targeted therapies for treating multiple solid tumor indications. Its lead therapeutic candidate, gedatolisib, is a potent inhibitor targeting the PI3K/AKT/mTOR pathway, currently being evaluated in several clinical trials for advanced breast cancer and metastatic castration-resistant prostate cancer. The company is headquartered in Minneapolis.

Average Trading Volume: 658,457

Technical Sentiment Signal: Buy

Current Market Cap: $1.39B

For detailed information about CELC stock, go to TipRanks’ Stock Analysis page.